While Kyverna Therapeutics Inc has underperformed by -5.48%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KYTX fell by -12.30%, with highs and lows ranging from $11.40 to $1.78, whereas the simple moving average fell by -9.89% in the last 200 days.
On May 27, 2025, H.C. Wainwright Upgraded Kyverna Therapeutics Inc (NASDAQ: KYTX) to Buy. A report published by UBS on October 10, 2024, Initiated its previous ‘Buy’ rating for KYTX. Rodman & Renshaw also rated KYTX shares as ‘Buy’, setting a target price of $16 on the company’s shares in an initiating report dated October 09, 2024. H.C. Wainwright Initiated an Neutral rating on July 03, 2024, and assigned a price target of $8. Wells Fargo initiated its ‘Overweight’ rating for KYTX, as published in its report on March 04, 2024. Morgan Stanley’s report from March 04, 2024 suggests a price prediction of $40 for KYTX shares, giving the stock a ‘Overweight’ rating. Leerink Partners also rated the stock as ‘Outperform’.
Analysis of Kyverna Therapeutics Inc (KYTX)
One of the most important indicators of Kyverna Therapeutics Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -49.72% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 7.44, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and KYTX is recording 347.81K average volume. On a monthly basis, the volatility of the stock is set at 10.57%, whereas on a weekly basis, it is put at 12.67%, with a gain of 6.84% over the past seven days. Furthermore, long-term investors anticipate a median target price of $17.20, showing growth from the present price of $3.28, which can serve as yet another indication of whether KYTX is worth investing in or should be passed over.
How Do You Analyze Kyverna Therapeutics Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 54.98%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 25.51% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
KYTX shares are owned by institutional investors to the tune of 25.51% at present.
